Teladoc Health (STU:4LL) Research & Development: €232 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4LL Teladoc Health Inc STU:4LL
51 GF Score
Price €5.81
GF Value €47.55
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Teladoc Health Research & Development?

Teladoc Health STU:4LL +2.22% 51 Research & Development is €232 Mil as of Jun. 2026. GuruFocus rates STU:4LL with a GF Score™ of 51/100 and a GF Value™ of €47.55 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Teladoc Health's Research & Development for the three months ended in Jun. 2026 was €55 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €232 Mil.

Teladoc Health  (STU:4LL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Teladoc Health Research & Development Related Terms

Teladoc Health Research & Development Historical Data

* Premium members only.

The historical data trend for Teladoc Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teladoc Health Research & Development Chart

Teladoc Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 276.02 314.95 319.59 293.45 237.35

Teladoc Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.64 57.57 61.15 58.70 54.56
STU:4LL
51GF Score
Teladoc Health Inc STU:4LL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teladoc Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €232 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €232 Mil mean?
Teladoc Health (STU:4LL) has a Research & Development of €232 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Teladoc Health and its competitors.
Is Teladoc Health's Research & Development too high?
Teladoc Health's current Research & Development is €232 Mil. Overall, Teladoc Health has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Teladoc Health's Research & Development compare to OMCL and OMDA?
Teladoc Health's Research & Development of €232 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Teladoc Health and its competitors. Teladoc Health's current Research & Development is €232 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teladoc Health stock overvalued right now?
Based on GuruFocus' analysis, Teladoc Health (STU:4LL) is currently considered Possible Value Trap. The stock's GF Value™ is €47.55, compared to a current price of €5.81 — trading 87.8% below its estimated fair value. The current Research & Development is €232 Mil. Teladoc Health's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Teladoc Health (STU:4LL), the current Research & Development is €232 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teladoc Health (STU:4LL) Overvalued in 2026?

Based on GuruFocus' analysis, Teladoc Health stock appears to be undervalued. The current stock price of €5.81 is trading 87.8% below its estimated GF Value™ of €47.55. GuruFocus considers Teladoc Health to be Possible Value Trap.

Key valuation signals for STU:4LL:

  • Research & Development: €232 Mil
  • GF Value™: €47.55 vs. price of €5.81 (87.8% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the STU:4LL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teladoc Health Business Description

Address 155 East 44th Street, Suite 1700, New York, NY, USA, 10017
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
51GF Score

Get the complete analysis for STU:4LL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.81
Price
€47.55
GF Value